Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 15/20 | 0.72 |
| ▸ | GSK3B | P49841 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2658009 | 1.00 | GCK (0.72) | GCKGSK3BLMNACLK1SMN1; SMN2 | |
| SCHEMBL3574645 | 0.93 | GCK (0.74) | GCK | |
| SCHEMBL2657166 | 0.93 | GCK (0.74) | GCK | |
| SCHEMBL2656493 | 0.93 | GCK (0.76) | GCKLMNASMN1; SMN2 | |
| SCHEMBL3567052 | 0.93 | GCK (0.76) | GCKLMNASMN1; SMN2 | |
| SCHEMBL8142670 | 0.92 | GCK (0.75) | GCK | |
| SCHEMBL2656335 | 0.92 | GCK (0.75) | GCK | |
| SCHEMBL3564385 | 0.92 | GCK (0.60) | GCKLMNACLK1SMN1; SMN2MEN1 | |
| SCHEMBL2658090 | 0.92 | GCK (0.60) | GCKLMNACLK1SMN1; SMN2MEN1 | |
| SCHEMBL3572390 | 0.88 | GCK (0.73) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1934180-B1 | 3-CYCLYL-2-(4-SULFAMOYL-PHENYL)-N-CYCLYL-PROPIONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF IMPAIRED GLUCOSE TOLERANCE AND DIABETES | NOVARTIS AG (CH) | 2012-12-05 | — | — | EP | claimed |
| US-7795257-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | claimed |
| US-20080318948-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | claimed |
| EP-1934180-B1 | 3-CYCLYL-2-(4-SULFAMOYL-PHENYL)-N-CYCLYL-PROPIONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF IMPAIRED GLUCOSE TOLERANCE AND DIABETES | NOVARTIS AG (CH) | 2012-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318948-A1 | Organic Compounds | GCK, GCKR, SLC2A2 | GCK 1/4885GSK3B 1143/4885LMNA 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.